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Introduction
Behcet’s disease (BD) is a systemic vasculitis with muco-
cutaneous, gastrointestinal, ocular, vascular, and neuro-
logical involvement.1 Ocular manifestations represent one
of major organ involvement, with a high rate of recur-
rences potentially resulting in partial or total blindness.
Treatments may range from the topical approach to dis-
ease-modifying antirheumatic drugs and biological
agents.1 Tumor necrosis factor (TNF)-a inhibitors and
interferon-a are usually effective in the majority of
patients with severe ocular disease.1
Recent clinical observations with the interleukin (IL)-1
inhibiting agents anakinra,2 canakinumab,3–5 and gevok-
izumab6 have suggested their potential role in the treat-
ment of refractory Behcet’s uveitis. Accordingly, in a
multicenter retrospective study, we found that treatment
with anakinra and canakinumab was effective and safe in
30 patients with BD, with an overall acceptable retention
on treatment.7
Unlike anti-TNFa treatment, IL-1 inhibition has shown
a good safety profile regarding the risk of severe infec-
tions, particularly in relation to tuberculosis (TB) reacti-
vation.8 Indeed, interfering with the IL-1 pathway seems
safer in comparison with blocking TNFa. This considera-
tion is relevant for patients with BD because of the high
prevalence of this disease in geographical areas where TB
is a social concern.8
In this regard, we report herein a patient with BD with
concomitant latent TB infection successfully treated with
anakinra as first-line biological therapy.
A 41-year-old man was diagnosed with BD in 2008
based on recurrent oral aphthosis, genital ulcerations,
and pseudofolliculitis. His medical history was also rele-
vant for monthly fever attacks, spontaneously resolved
1 year after the onset of symptoms, hip arthralgia, and
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abdominal pain with diarrhea without evidence of inflam-
matory lesions at colonoscopy. No mutations in the
MEFV gene, responsible for familial Mediterranean fever,
were detected. BD symptoms were controlled with colchi-
cine 1 mg/d until February 2014, when a bilateral ante-
rior non-granulomatous uveitis occurred. Although on
prednisone 1 mg/kg per day, in March 2014 the patient
was admitted to our unit for continuous fever, recurrent
oral ulcerations, and progressive worsening vision in the
right eye. The ophthalmological evaluation revealed acute
papillitis and a best-corrected visual acuity (BCVA) of
20/400 in the right eye, while the left eye was normal.
Laboratory examinations, abdominal ultrasound, and a
chest computed tomography did not show abnormalities.
The Quantiferon test was positive. Treatment with corti-
costeroids (6-methylprednisolone 500 mg/d intravenously
for 3 consecutive days followed by shortly tapering oral
prednisone until 5 mg/d) and anakinra (100 mg/d subcu-
taneously) was started. Of note, no other disease-modify-
ing antirheumatic drugs were used before starting
anakinra. Despite the use of high-dose corticosteroids
and anakinra, anti-TB prophylaxis was not administered
because of proven multiple intolerance to anti-TB drugs;
in particular, isoniazid and rifampicin were early inter-
rupted due to gastrointestinal (nausea and vomit) and
cutaneous (generalized urticaria) manifestations. A good
clinical response was rapidly achieved, and the ophthal-
mologic evaluation performed 7 days after starting the
treatment showed a dramatic visual improvement and a
marked reduction of the optic nerve head swelling. Fur-
ther ophthalmological evaluations performed every
2 months highlighted resolution of papillitis, increase of
BCVA to 20/25, and absence of ocular inflammation dur-
ing the following 12 months (Fig. 1). Anakinra treatment
was well tolerated, and no adverse events or signs of TB
reactivation occurred.
Anti-IL-1 agents are emerging as an important thera-
peutic option in BD,2–7 with a good safety profile.9 IL-1
is a proinflammatory cytokine secreted by a wide number
of cell types, and increased levels of IL-1 play a major
role in several disorders including autoinflammatory
diseases.10,11 In this regard, BD shows several clinical
findings overlapping with those of autoinflammatory
diseases;12 moreover, polymorphisms in the IL-1-related
genes have proven to confer susceptibility to BD.13
Interestingly, recent data have shown that IL-1b from
peptidoglycan/lipopolysaccharide-induced monocytes is
significantly increased in patients with BD with active
uveitis, thus providing a pathophysiological rationale for
anti-IL-1 treatment in Behcet’s uveitis.14
Noteworthy, our patient presented a positive Quantif-
eron-TB test, thus deserving some attention when starting
anti-TNFa treatment. In fact, the risk of TB reactivation
when using anti-TNFa agents represents a hot issue par-
ticularly in those areas where the infection is endemic,
such as along the ancient Silk Road, where BD has a high
prevalence and TB is a socioeconomic burden. Con-
versely, IL-1 inhibitors have shown a better safety profile
than anti-TNFa regarding the risk of TB reactivation.8
Our report suggests that anakinra should not be
reserved only to refractory patients with BD but high-
lights that in selected BD cases it should be taken into
consideration also as a first-line biologic drug. This might
be relevant particularly when a rapid and persistent thera-
peutic response is needed, but at the same time, con-
traindications to anti-TNFa treatment, such as the
concomitant TB infection in our patient, are present.
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